Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.International vaccine adjuvant company Isconova has presented data from the human PanFluVac trial evaluating the safety and the immunogenicity of an avian flu vaccine adjuvanted with Matrix M.
Subscribe to our email newsletter
In the phase I clinical study, comprising a total of 60 healthy volunteers, Matrix M demonstrated positive results.
The study was conducted at The Gade Institute, University of Bergen, Norway and funded by the European Commission through the PanFluVac research consortium.
The volunteers were vaccinated with the virosomal vaccine alone or with three different doses of the vaccine formulated with Matrix M.
Matrix M increased the efficacy of the vaccine considerably and the adjuvanted vaccines met all the efficacy criteria of the study.
Isconova CEO Lena Söderström said the PanFluVac trial was a major milestone for Isconova as it was the first time Isconova’s adjuvant Matrix M was tested in humans.
"There is a clear unmet medical need for better and more effective vaccines, and the results of the PanFluVac trial are further evidence that Matrix M can address this important market," Söderström said.